Financhill
Buy
53

ALNY Quote, Financials, Valuation and Earnings

Last price:
$264.97
Seasonality move :
-5.65%
Day range:
$251.23 - $265.02
52-week range:
$141.98 - $304.39
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
16.04x
P/B ratio:
1,056.40x
Volume:
928.3K
Avg. volume:
638.2K
1-year change:
43.99%
Market cap:
$34.2B
Revenue:
$1.8B
EPS (TTM):
-$2.62

Analysts' Opinion

  • Consensus Rating
    Alnylam Pharmaceuticals has received a consensus rating of Buy. The company's average rating is a Buy based on 11 Buy ratings, 8 Hold ratings, and 1 Sell rating.
  • Price Target Upside
    According to analysts' consensus price target of $299.71, Alnylam Pharmaceuticals has an estimated upside of 13.1% from its current price of $264.99.
  • Price Target Downside
    According to analysts, the lowest downside price target is $200.00 representing 24.53% downside risk from its current price of $264.99.

Fair Value

  • According to the consensus of 20 analysts, Alnylam Pharmaceuticals has 13.1% upside to fair value with a price target of $299.71 per share.

ALNY vs. S&P 500

  • Over the past 5 trading days, Alnylam Pharmaceuticals has overperformed the S&P 500 by 0.7% suggesting its relative strength compared to the major market average is strong at this time.

Share Buyback

  • Alnylam Pharmaceuticals does not have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.

Revenue Growth

  • Alnylam Pharmaceuticals revenues have been falling on a year-over-year basis for 1 quarter in a row. In the most recent quarter Alnylam Pharmaceuticals reported revenues of $500.9M.

Earnings Growth

  • Alnylam Pharmaceuticals has grown year-over-year earnings for 0 quarters straight. In the most recent quarter Alnylam Pharmaceuticals reported earnings per share of -$0.87.
Enterprise value:
32.4B
EV / Invested capital:
--
Price / LTM sales:
16.04x
EV / EBIT:
465.26x
EV / Revenue:
15.48x
PEG ratio (5yr expected):
--
EV / Free cash flow:
2,018.43x
Price / Operating cash flow:
2,091.33x
Enterprise value / EBITDA:
192.67x
Gross Profit (TTM):
$1.8B
Return On Assets:
-8.43%
Net Income Margin (TTM):
-15.86%
Return On Equity:
--
Return On Invested Capital:
-36.66%
Operating Margin:
-15.35%
Trailing 12 Months Fiscal Quarters
Period Ending 2022-09-30 2023-09-30 2024-09-30 2023-09-30 2024-09-30
Income Statement
Revenue $960.9M $1.7B $2.1B $750.5M $500.9M
Gross Profit $805.7M $1.4B $1.8B $666.2M $415M
Operating Income -$791M -$354.4M -$188.1M $213.9M -$76.9M
EBITDA -$935.3M -$285.1M -$85.7M $205.2M -$47.2M
Diluted EPS -$9.77 -$4.14 -$2.62 $1.15 -$0.87
Period Ending 2020-09-30 2021-09-30 2022-09-30 2023-09-30 2024-09-30
Balance Sheet
Current Assets $2.1B $2.7B $2.7B $3B $3.4B
Total Assets $3.3B $3.5B $3.5B $3.8B $4.2B
Current Liabilities $480.2M $610.7M $772.8M $949.8M $1.2B
Total Liabilities $2.1B $2.7B $3.6B $4B $4.2B
Total Equity $1.2B $755.9M -$67.6M -$165.9M $32.4M
Total Debt -- $433.8M $1B $1B $1B
Trailing 12 Months Fiscal Quarters
Period Ending 2022-09-30 2023-09-30 2024-09-30 2023-09-30 2024-09-30
Cash Flow Statement
Cash Flow Operations -$559.4M $2M $56.6M $359.4M $43.7M
Cash From Investing -$104.1M -$235.6M -$304.6M -$10.8M -$30.3M
Cash From Financing $654.6M $196.3M $302.4M $33.1M $102.8M
Free Cash Flow -$631.7M -$66.6M $16.1M $342.3M $39.5M
ALNY
Sector
Market Cap
$34.2B
$45.7M
Price % of 52-Week High
87.06%
47.48%
Dividend Yield
0%
0%
Shareholder Yield
--
-0.75%
1-Year Price Total Return
43.99%
-32.34%
Beta (5-Year)
0.342
0.746
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Technicals

8-day SMA
Buy
Level $248.59
200-day SMA
Buy
Level $228.82
Bollinger Bands (100)
Buy
Level 244.05 - 278.97
Chaikin Money Flow
Buy
Level 72.1M
20-day SMA
Buy
Level $242.37
Relative Strength Index (RSI14)
Buy
Level 61.89
ADX Line
Buy
Level 27.41
Williams %R
Sell
Level -0.0882
50-day SMA
Buy
Level $248.91
MACD (12, 26)
Buy
Level 1.06
25-day Aroon Oscillator
Buy
Level 36
On Balance Volume
Neutral
Level 104.7M

Financial Scores

Hold
Altman Z-Score (Annual)
Level (1.844)
Sell
CA Score (Annual)
Level (-3.184)
Buy
Beneish M-Score (Annual)
Level (-2.6252)
Buy
Momentum Score
Level (9)
Sell
Ohlson Score
Level (4.0138)
Buy
Piotroski F Score (Annual)
Level (6)
Buy
Quality Ratio Score
Level (6)
Buy
Fundamental Score
Level (4)

Revenue Forecast

Earnings per Share Forecast

Company Profile

Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia. It also has several clinical programs across various therapeutic areas: genetic medicines; cardio-metabolic diseases; hepatic infectious diseases, and CNS/ocular diseases. Upfront fees from research partnerships have boosted Alnylam's cash levels, and the company stands to see additional milestones and royalties from drugs commercialized under collaboration partnerships.

Stock Forecast FAQ

In the current month, ALNY has received 11 Buy ratings 8 Hold ratings, and 1 Sell ratings. The ALNY average analyst price target in the past 3 months is $299.71.

  • Where Will Alnylam Pharmaceuticals Stock Be In 1 Year?

    According to analysts, the consensus estimate is that Alnylam Pharmaceuticals share price will rise to $299.71 per share over the next 12 months.

  • What Do Analysts Say About Alnylam Pharmaceuticals?

    Analysts are divided on their view about Alnylam Pharmaceuticals share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Alnylam Pharmaceuticals is a Sell and believe this share price will drop from its current level to $200.00.

  • What Is Alnylam Pharmaceuticals's Price Target?

    The price target for Alnylam Pharmaceuticals over the next 1-year time period is forecast to be $299.71 according to 20 Wall Street analysts, 11 of them rate the stock a Buy, 1 rates the stock a Sell, and 8 analysts rate the stock a Hold.

  • Is ALNY A Buy, Sell Or Hold?

    According to Wall Street analysts, the consensus rating for Alnylam Pharmaceuticals is a Buy. 11 of 20 analysts rate the stock a Buy at this time.

  • How Can I Buy Shares Of ALNY?

    You can purchase shares of Alnylam Pharmaceuticals via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, TastyTrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Alnylam Pharmaceuticals shares.

  • What Is The Alnylam Pharmaceuticals Share Price Today?

    Alnylam Pharmaceuticals was last trading at $264.97 per share. This represents the most recent stock quote for Alnylam Pharmaceuticals. Yesterday, Alnylam Pharmaceuticals closed at $264.99 per share.

  • How To Buy Alnylam Pharmaceuticals Stock Online?

    In order to purchase Alnylam Pharmaceuticals stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

Is Philip Morris Stock Overvalued?
Is Philip Morris Stock Overvalued?

If there is one industry that can be termed truly…

What Quantum Stocks Should I Buy?
What Quantum Stocks Should I Buy?

The last several years have seen a series of tech…

Will Sirius XM Be a 10-Bagger Stock?
Will Sirius XM Be a 10-Bagger Stock?

Last year, Warren Buffett surprised practically everyone when he acquired…

Stock Ideas

Buy
52
Is NVDA Stock a Buy?

Market Cap: $3.4T
P/E Ratio: 118x

Sell
43
Is AAPL Stock a Buy?

Market Cap: $3.3T
P/E Ratio: 37x

Buy
51
Is MSFT Stock a Buy?

Market Cap: $3.2T
P/E Ratio: 36x

Alerts

Sell
49
RKLB alert for Jan 22

Rocket Lab USA [RKLB] is up 30.42% over the past day.

Sell
32
FTAI alert for Jan 22

FTAI Aviation [FTAI] is down 25.44% over the past day.

Sell
2
EDU alert for Jan 22

New Oriental Education & Technology Group [EDU] is down 23.18% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock